(Reuters) – Goldman Sachs-backed drug developer Septerna said on Thursday it was seeking a valuation of $743.1 million in its upsized initial public offering in the United States.
The company now aims to raise $275 million by selling nearly 15.3 million shares priced at $18 apiece.
Septerna had earlier planned on selling about 10.9 million shares at a price range of $15 to $17 each.
J.P. Morgan, TD Cowen, Cantor, and Wells Fargo Securities are the underwriters for the offering.
Septerna expects to list on the Nasdaq under the symbol “SEPN.”
(Reporting by Arasu Kannagi Basil in Bengaluru; Editing by Shailesh Kuber)
Comments